Therefore, in our animal experiments, CTLA-4 blockade therapy was introduced, aiming at enhancing the anti-cancer therapeutic efficacy of ‘tumour vaccines' that are in situ generated after PLGA-ICG-R837-based photothermal ablation of primary tumours. The gene discussed is CTLA4; the disease is neoplasm.